Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04146324
Recruitment Status : Not yet recruiting
First Posted : October 31, 2019
Last Update Posted : October 31, 2019
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
This study is designed to estimate the effectiveness of nivolumab when given to participants after removing their cancer with surgery, over a 5-year follow-up, in real-world conditions in Australia.

Condition or disease Intervention/treatment
Melanoma Drug: nivolumab

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective Observational Study in Patients Receiving Adjuvant Nivolumab Therapy for Resected Melanoma in Australia
Estimated Study Start Date : October 31, 2019
Estimated Primary Completion Date : July 9, 2025
Estimated Study Completion Date : July 9, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Nivolumab

Group/Cohort Intervention/treatment
Adjuvant nivolumab therapy
Participants receiving nivolumab as an adjuvant therapy according to the market authorization in Australia
Drug: nivolumab
Administered as adjuvant therapy as per the market authorization in Australia




Primary Outcome Measures :
  1. Percentage of Participants with Relapse-Free Survival (RFS) [ Time Frame: Up to 5 years post treatment initiation with adjuvant nivolumab therapy ]
    The time between the date of randomisation and the date of first recurrence, new primary melanoma, or death due to any cause, whichever occurred first.


Secondary Outcome Measures :
  1. Percentage of Participants with Distant Metastasis-Free Survival (DMFS) [ Time Frame: Up to 5 years post treatment initiation with adjuvant nivolumab therapy ]
  2. Overall Survival (OS) [ Time Frame: Up to 5 years post treatment initiation with adjuvant nivolumab therapy ]
  3. Description of sociodemographic profile of participants [ Time Frame: At treatment initiation with adjuvant nivolumab therapy ]
  4. Description of clinical characteristics of participants [ Time Frame: At treatment initiation with adjuvant nivolumab therapy ]
  5. Prior medical history of participants [ Time Frame: At treatment initiation with adjuvant nivolumab therapy ]
  6. Description of nivolumab pattern of use [ Time Frame: At treatment initiation with adjuvant nivolumab therapy ]
  7. Health-related quality of life (HRQOL) of participants as assessed by European Quality of Life Five Dimensional Scale (EuroQOL-5D/EQ-5D) [ Time Frame: Up to 5 years post treatment initiation with adjuvant nivolumab therapy ]
  8. HRQOL of participants as assessed by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ C-30) [ Time Frame: Up to 5 years post treatment initiation with adjuvant nivolumab therapy ]
  9. HRQOL of participants as assessed by Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire [ Time Frame: Up to 5 years post treatment initiation with adjuvant nivolumab therapy ]
  10. Participants' socioeconomic status as assessed by their highest education level [ Time Frame: At treatment initiation with adjuvant nivolumab therapy ]
  11. Description of care received as assessed by Healthcare Resource Utilization [ Time Frame: During, and up to 5 years post discontinuation of nivolumab use ]
  12. Number of participants experiencing immune-related Adverse Events (AEs) [ Time Frame: Up to 5 years post treatment initiation with adjuvant nivolumab therapy ]
  13. Number of participants experiencing non-immune-related AEs [ Time Frame: Up to 5 years post treatment initiation with adjuvant nivolumab therapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adults whose melanoma had spread to the lymph nodes or other parts of the body and was surgically removed, and who are receiving post-surgery treatment with nivolumab to decrease the risk of cancer coming back.
Criteria

Inclusion Criteria:

  • Adults with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete surgical removal and have no evidence of disease
  • Decision to treat with adjuvant nivolumab therapy has already been taken
  • Ability to provide written informed consent to participate in the study

Exclusion Criteria:

  • Adults with a current diagnosis of persisting advanced melanoma
  • Adults currently enrolled in an interventional clinical trial for his/her melanoma treatment

Other Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04146324


Contacts
Layout table for location contacts
Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #

Locations
Layout table for location information
Australia, Australia Capital Territory
Local Institution
Canberra, Australia Capital Territory, Australia, 2600
Contact: Site 0004         
Australia, Queensland
Local Institution
Birtinya, Queensland, Australia, 4575
Contact: Site 0011         
Local Institution
Cairns, Queensland, Australia, 4870
Contact: Site 0010         
Local Institution
Greenslopes, Queensland, Australia, 4120
Contact: Site 0001         
Local Institution
Herston, Queensland, Australia, 4031
Contact: Site 0008         
Local Institution
Woolloongabba, Queensland, Australia, 4012
Contact: Site 0005         
Australia, South Australia
Local Institution
Adelaide, South Australia, Australia, 5000
Contact: Site 0007         
Local Institution
Woodville South, South Australia, Australia, 5001
Contact: Site 0006         
Australia, Victoria
Local Institution
Box Hill, Victoria, Australia, 3128
Contact: Site 0002         
Local Institution
Malvern, Victoria, Australia, 3144
Contact: Site 0003         
Local Institution
Melbourne, Victoria, Australia, 3004
Contact: Site 0009         
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb

Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT04146324    
Other Study ID Numbers: CA209-7CK
First Posted: October 31, 2019    Key Record Dates
Last Update Posted: October 31, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bristol-Myers Squibb:
Adjuvant
nivolumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents